Le Lézard
Classified in: Health, Science and technology, Business
Subjects: EARNINGS, Conference Call, Webcast, Advisory

Twist Bioscience to Report Fiscal 2022 Fourth Quarter and Full Year Financial Results on Friday, November 18, 2022


Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that it will issue its financial results for the fiscal 2022 fourth quarter and full year ended September 30, 2022, before the opening of the market on Friday, November 18, 2022. The company plans to hold a conference call and live audio webcast for analysts and investors at 8:00 a.m. Eastern Time to discuss its financial results and provide an update on the company's business. The press release with the financial results will be accessible from the company's website prior to the conference call through the Investor Relations section under the "Company" tab at www.twistbioscience.com.

The conference call will be webcast live through the Investor Relations section under the "Company" tab at www.twistbioscience.com. Those parties interested in participating via telephone must register on the Company's Investor Relations website or by clicking here. Upon registration, all telephone participants will receive the dial-in number along with a unique PIN number that can be used to access the call. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. The webcast replay will be available for two weeks.

About Twist Bioscience Corporation

Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by "writing" DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.

Follow us on Twitter | Facebook | LinkedIn | YouTube


These press releases may also interest you

25 avr 2024
AZZ Inc. , the leading independent provider of hot-dip galvanizing and coil coating solutions, today announced the pricing of its underwritten public offering of 4,000,000 shares of common stock at a public offering price per share of $70.00, for...

25 avr 2024
CarLotz, Inc.  Accused of Misleading Investors On March 29, 2024, the defendants' motion to dismiss in the pending securities class...

25 avr 2024
TSX VENTURE COMPANIES BULLETIN V2024-1200 LEONOVUS INC. ("LTV.WT")BULLETIN TYPE:  Warrant Expiry-DelistBULLETIN DATE:  April 25, 2024TSX Venture Tier 2 Company Effective at the opening, May 2, 2024, the Share Purchase Warrants of the Company will...

25 avr 2024
Greenbrook TMS Inc. ("Greenbrook" or the "Company") today announced its fiscal year ended December 31, 2023 ("Fiscal 2023") operational and financial results. All values in this news release are in United States dollars, unless otherwise stated....

25 avr 2024
Dominion Lending Centres Inc. ("DLCG" or the "Corporation") is pleased to announce that it has completed a sale of its 52% interest in Cape Communications International Inc. ("Impact") for aggregate cash proceeds of $3.71 million (the "Purchase...

25 avr 2024
Orbia Advance Corporation, S.A.B. de C.V. (BMV: ORBIA*) ("the Company" or "Orbia") today released unaudited results for the first quarter of 2024. Orbia's first quarter performance reflects the continued weakness in the market environment,...



News published on and distributed by: